- BJP tears into UPA govt on 4th anniversary, says it lacks leadership
- Madras High Court issues notice to BCCI, Sports Minister over IPL spot-fixing
- Jessica Lal murder: Actor Shayan Munshi, ballistic expert Manocha to face perjury trial
- India seeks access from US to 26/11 terror convicts Headley, Rana
- Govt further cuts import tariff value of gold
Capita loses UK criminal records contract to TCS
British outsourcing firm Capita said on Wednesday it had lost out on a new government contract to run criminal records checks after the Home Office pursued talks with a rival supplier. The trade union representing staff under Capita's existing contract said the coalition government is likely to award the deal to Tata Consultancy Services, part of Tata Group. Analysts also expected TCS to get the nod. Capita has run the UK's Criminal Records Bureau disclosure service for over 10 years under a deal worth around £400 million ($650 million), and had hoped to secure a similar contract to support the replacement Disclosure and Barring Service (DBS).
Pfizer to appeal decision to revoke Sutent patent
Pfizer, the India unit of US drugmaker Pfizer Inc, will challenge the country's patent office for revoking a patent for its cancer drug Sutent. The company, which will appeal before the Intellectual Property Appellate Board, said on Friday the Indian Patent Office's decision raised concerns over India's commitment to protect intellectual property.
"We believe the decision undermines intellectual property rights in India and we will vigorously defend our basic Sutent patent," Jazz Tobaccowalla, managing director of Pfizer India, said.
Parry Nutra to market its US arm's products
Parry Nutraceuticals, a division of EID Parry (I), has decided to market a host of wellness products of its US subsidiary, US Nutraceuticals, into the Indian market through 'Parry's Wellness' brand to tap the R10,000-crore nutraceuticals market in India, said Sajiv Menon, business head, Parry Nutraceuticals. Speaking to FE, he said: "We are marketing number of products, which are being developed in India, through 22,000 outlets across the country in the OTC format. We have decided to introduce some of the products of our US subsidiary (formerly Valensa) into India in the next three to six months."
- Fixing probe now reaches Bollywood, son of Dara Singh held
- BCCI cashes Pune Warriors guarantee, 'disgusted' Sahara walks out of IPL
- Sreesanth spent Rs 1.95L on clothes, bought friend BlackBerry, paid in cash: Police
- Delhi firm with MoD as client is linked to Pak cyberattacks
- After Infosys, iGATE sacks Phaneesh Murthy for sexual misconduct
- 2 weeks after harassment, Haryana schoolgirls return, cops in tow